Hello Mark & nmusers,
I'm just catching up with the flurry of emails on this topic...
I don't think that anyone mentioned full model approaches to
covariate modeling, although we have discussed this topic in detail
in past nmusers threads. Frank Harrell's Regression Modeling
Strategies tex
Dear NMUSERS:
A few openings remain for upcoming pharmacometrics training courses
at Metrum Institute* (see http://metruminstitute.org/training.html
for registration and complete course outlines):
Introduction to Bayesian PK-PD Modeling and Simulation
This 3-day on-site course provides an i
Tom, nmusers:
Here's a suggestion that might be helpful if file names are long
because of a long file path.
NMTRAN does recognize relative path designations, using the location
of the control file as the relative reference.
For example...
If the data file is in:
C:\LongDirecotryName\LongDir
Hi Pete -
You can do this through trial simulation/estimation or through
information theoretic approaches (e.g. POPT, PFIM, PopED, etc.). Both
methods will give you an estimate of expected parameter estimation
precision under a given design. Simulation/estimation approaches will
also provi
(apologies for duplicate postings)
Metrum Institute is pleased to announce the 2008 offering of our
popular training series in population PK-PD modeling. Both of these
courses (MI210, MI212) are offered as live web-cast training
sessions, with hands-on practice problems and weekly lab sessi
[apologies for duplicate postings]
Metrum Institute spring/summer 2008 training course offerings include
three intensive, hands-on, courses. Two of these courses are repeat-
performances of popular topics, including essential skills in
population PKPD and Bayesian PKPD modeling methods. The
Andreas,
You've raised an important, but sometimes overlooked, point about
model checking using simulation-based methods. As Andrew Gelman points
out in the reference below, when comparing simulated vs observed
values you need to compare apples to apples. Either incorporate a
model for the
Steve - Thanks for making the point about the importance of
experimental design. Often times when pooling adult and pediatric
data, data are imbalanced, and pediatric PK designs are much less
informative than the adult data. If, for a particular drug and disease
state, pediatric patients re
Metrum Institute Announces a New Course OfferingMI101-W: Introduction to Pharmacokinetics and PharmacodynamicsThis course provides a thorough introduction to fundamental concepts in pharmacokinetics and pharmacodynamics through lectures and problem-solving lab sessions that emphasize physiologic co
There's an additional, related point to consider with respect to
estimation method, in selecting a simultaneous vs sequential
approach
In the case where simultaneous modeling under conditional estimation
is not feasible (run-time, convergence, etc), it is preferable to use
a sequentia
Ethan,
As Leonid suggests, you may want to control NONMEM runs using an
external tool and an INFN routine for extraction of results. MIfuns,
an open-source R package, provides functions for this sort of
automation. Template INFN codes are provided as well. It's a free
download:
http://met
Metrum Institute is pleased to announce several training course
offerings for 2009!
We've added two new courses this year: MI101: Introduction to
Pharmacokinetics and Pharmacodynamics, and MI220: R Programming for
Pharmacometrics. In addition, our popular introductory Bayesian
modeling c
(Apologies for the delayed posting.. this apparently didn't make it to
nmusers on the initial attempt).
Dear Nick, Andreas, Andreas and nmusers,
Here are a couple of additional methods for including uncertainty in
parameters at the inter-trial (or inter-replicate) level, when
simulating wi
ity of our computer systems and checking
compliance with our Code of Conduct and policies.
-Original Message-
From: owner-nmus...@globomaxnm.com [mailto:owner-nmus...@globomaxnm.com
]On Behalf Of Gastonguay, Marc
Sent: 16 July 2009 18:59
To: nmusers
Subject: Re: AW: [NMusers] Simulations wi
Metrum Institute* is pleased to announce a new hands-on, intensive 3-
day course (MI260+) scheduled for September 2, 3, & 4, 2009 in
Cambridge, MA. This offering will combine an introduction to WinBUGS
for pharmacokinetic/pharmacodynamic applications, with a detailed
overview of Bayesian mod
Hello Jakob, et al.
I would agree that individuals who do not contribute data to the
estimation of a particular element of OMEGA should be excluded from
the ETA-shrinkage calculation or ETA-based diagnostics. I think that
using individual ETA=0 as the filtering criterion may be a reasonable
Hello Ethan,
This archived NMusers discussion thread might be useful:
http://cognigencorp.com/nonmem/nm/97dec172003.html
Marc
Marc R. Gastonguay, Ph.D.
President & CEO, Metrum Research Group LLC < metrumrg.com >
Scientific Director, Metrum Institute < metruminstitute.org >
2 Tunxis Rd, Suite 1
e code in
>
>
>
> http://cognigencorp.com/nonmem/nm/97dec172003.html somwhere? I
> try to implement a second-order autoregressive process. If
> C(J,1) is a correlation coefficient, can I use more complex
> equations for C(j,1)? Will this code work if we use ADVAN13 (PD
> mode
Metrum Institute is pleased to announce several course offerings for
2010, as both on-site short-courses and semester-long webinar series.
Some of the newer offerings include courses on Bayesian methods (using
WinBUGS) applied to PK-PD, categorical/time-to-event endpoints, and
model-based
Vincenzo / Amit:
A quick inspection of your code reveals a typo in the denominator of
your probability expression.
P = EXP(A)/1+EXP(A)
should be:
P = EXP(A)/ (1+EXP(A))
Due to FORTRAN order of operation, you need the parentheses around the
entire term (1+EXP(A)).
Hope this helps.
Marc
Matts,
You should be cautious about implementing this example as you've parameterized
the model. There is an inconsistency between your model parameterization and
the multivariate-normal assumption made when you use the var-cov matrix of the
estimates to incorporate parameter uncertainty. See ea
Dear Joann,
If your goal is to learn about the the effect of CLCR on CLM2, you'll need to
keep this effect in the model.
If your goal is to reduce IIV, then it appears you could exclude this effect,
but you won't learn anything about the effect of CLCR on CLM2.
Keep in mind that your estimate
In an effort to save our inboxes from this continuous onslaught of shameless
plugs, I'd suggest you take a look at the PAGE meeting website
(http://www.page-meeting.org/) for an extensive list of service providers. It
would also be a good idea to visit and perform site audits of prospective
ven
Dear Charles,
When using $PRIOR, the df specifies the degrees of freedom for the
Inverse-Wishart prior distribution on the covariance matrix of the
individual random effects (OMEGA). In practical terms, the larger the df,
the more informative the prior will be. It's not surprising, then, that
your
As part of Metrum Institute's continuing efforts to support and grow the
discipline of pharmacometrics, we are pleased to announce the public
availability of our series of pharmacometrics training lectures at no cost.
Video recordings and lecture notes from six semester-long courses (MI205,
MI210,
Dear Justus,
On the second dosing record, code SS = 2 for superposition of a second SS
dose. SS = 1 will ignore prior dosing records.
Best regards,
Marc
On Wed, Mar 5, 2014 at 9:51 PM, Justus Bingham <
jus...@cascadepharmaceutical.com> wrote:
> Dear NMUSERS,
>
> I am having problems simulating si
Douglas makes important point in this discussion. That is, the method used
to judge parsimony of the model must consider the performance of the model
for intended purpose.
Consider the parsimony principle: "all things being equal, choose the
simpler model". The key is in how to judge the first par
We are pleased to announce registration is now open for:
*THE SHEINER/ROWLAND ADVANCED COURSE IN PHARMACOKINETICS/PHARMACODYNAMICS*
*Co-sponsored by Sanofi and Metrum Research Group *
Date: Sunday March 15, 2015 - Friday March 20, 2015
Lambertville Station Inn & Restaurant
Lambertville, Ne
Just a reminder that seats are still available for:
*THE SHEINER/ROWLAND ADVANCED COURSE IN PHARMACOKINETICS/PHARMACODYNAMICS*
*Co-sponsored by Sanofi and Metrum Research Group*
Date: Sunday March 15, 2015 - Friday March 20, 2015
Lambertville Station Inn & Restaurant
Lambertville, New Jers
Bob, Tom:
Thanks for sharing this explanation.
Users might actually be interested in conducting simulations from a model that
terminates with rounding errors for diagnostic or other purposes. I wonder if
the NONMEM project group might consider a different default MSF behavior?
Instead of an er
Nick, Jakob, nmusers:
At the risk of re-opening an old discussion, I'd like to expand on Nick's
important point. From our experience the experience of others, including
parameters from all bootstrap runs that report parameter estimates, regardless
of minimization of $COV status, is a reasonable
31 matches
Mail list logo
